Administration of aluminium to neonatal mice in vaccine-relevant amounts is associated with adverse long term neurological outcomes

• Aluminium (Al) salts are the most widely used vaccine adjuvants today.
• Al adjuvants can persist in the body long-term and penetrate the blood-brain barrier.
• Al adjuvants can trigger adverse neurobehavioral outcomes in vaccine-relevant exposures.
• Efforts should be made to reduce Al exposure from vaccines.

Our previous ecological studies of autism spectrum disorder (ASD) has demonstrated a correlation between increasing ASD rates and aluminium (Al) adjuvants in common use in paediatric vaccines in several Western countries. The correlation between ASD rate and Al adjuvant amounts appears to be dose-dependent and satisfies 8 of 9 Hill criteria for causality. We have now sought to provide an animal model to explore potential behavioural phenotypes and central nervous system (CNS) alterations using s.c. injections of Al hydroxide in early postnatal CD-1 mice of both sexes. Injections of a “high” and “low” Al adjuvant levels were designed to correlate to either the U.S. or Scandinavian paediatric vaccine schedules vs. control saline-injected mice. Both male and female mice in the “high Al” group showed significant weight gains following treatment up to sacrifice at 6 months of age. Male mice in the “high Al” group showed significant changes in light–dark box tests and in various measures of behaviour in an open field. Female mice showed significant changes in the light–dark box at both doses, but no significant changes in open field behaviours. These current data implicate Al injected in early postnatal life in some CNS alterations that may be relevant for a better understanding of the aetiology of ASD.

Repetitive administration of aluminium to neonatal mice in amounts comparable to those to children receive via routine vaccinations significantly increases anxiety and reduces exploratory behaviour and locomotor activities. The neurodisruptive effects of aluminium are long-lasting and persist for 6 months following injection.Figure optionsDownload as PowerPoint slide